Health Care [ 5/12 ] | Biotechnology [ 33/74 ]
NASDAQ | Common Stock
NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States.
It operates through NRx and Dura segments.
The company develops NRX-101, an oral fixed-dose combination of D-cycloserine (DCS) and lurasidone in Phase 2/3 clinical testing for bipolar depression with sub-acute ideation and behavior; NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression; and KETAFREE, a generic preservative-free formulation of ketamine.
It also provides precision-based interventional psychiatry services to patients with treatment-resistant depression and PTSD using a combination of neuroplastic drugs, transcranial magnetic stimulation (TMS), digital therapeutics, and hyperbaric therapy; ketamine infusion therapy; stellate ganglion blocks; Spravato administration; psychotherapy; and medication management.
The company has a development and license agreement with Glytech LLC.
NRx Pharmaceuticals, Inc. was founded in 2015 and is headquartered in Wilmington, Delaware.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 18, 26 | -0.04 Increased by +86.94% | -0.11 Increased by +59.64% |
| Mar 24, 26 | 0.18 Increased by +123.81% | -0.08 Increased by +329.13% |
| Nov 14, 25 | -0.27 Decreased by -80.00% | -0.52 Increased by +48.08% |
| Aug 18, 25 | -0.98 Decreased by -46.27% | -0.53 Decreased by -84.91% |
| May 15, 25 | -0.34 Increased by +54.05% | -0.53 Increased by +35.85% |
| Mar 26, 25 | -0.77 Decreased by -54.00% | -0.37 Decreased by -108.11% |
| Nov 11, 24 | -0.15 Decreased by -114.29% | -0.64 Increased by +76.56% |
| Aug 14, 24 | -0.67 Decreased by -458.33% | -0.69 Increased by +2.90% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 26 | 1.07 M Increased by +26.60 K% | -1.43 M Increased by +74.06% | Decreased by -133.90% Increased by +99.90% |
| Dec 31, 25 | 983.00 K Increased by +24.48 K% | 360.00 K Increased by +103.97% | Increased by +36.62% Increased by +100.02% |
| Sep 30, 25 | 242.00 K Increased by +N/A% | -5.89 M Decreased by -262.91% | Decreased by -2.43 K% Decreased by N/A% |
| Jun 30, 25 | 0.00 Decreased by N/A% | -17.58 M Decreased by -122.63% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 25 | 4.00 K Decreased by -50.00% | -5.51 M Increased by +15.56% | Decreased by -137.80 K% Decreased by -68.87% |
| Dec 31, 24 | 4.00 K Decreased by -50.00% | -9.08 M Decreased by -109.56% | Decreased by -226.95 K% Decreased by -319.11% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -1.62 M Increased by +73.23% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -7.90 M Increased by +9.41% | Decreased by N/A% Decreased by N/A% |